Our integrative multi-omics analysis, combined with epitope-level validation, identifies a biomarker panel RFC2, HSP90AB1, YWHAZ, CYP2E1, and ADH4 capable of distinguishing HCC with high accuracy. This evidence concerns the gene ADH4 and hepatocellular carcinoma.